Key Wins In US By Indian Firms - Keep An Eye On These In 2019
Executive Summary
2018 saw front-line Indian companies receive some key product approvals in the US or sew up large or niche M&A transactions there. How these play out could have a material impact on the growth outlook of these firms in 2019.
You may also be interested in...
Biocon Biologics Reaches Landmark Sales Figure As IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
Biocon Biologics Reaches Landmark Sales Figure; IPO Beckons
Biocon rang in a strong fourth quarter amid signs of a build-up in efforts towards supporting the “independent functioning” of its biosimilars business under subsidiary Biocon Biologics.
India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)
2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.